HLA-A2 tumor associated antigen peptides and compositions
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/04
A61K-038/16
A61P-035/00
C07K-014/47
A61K-039/00
C07K-007/06
출원번호
US-0081086
(2013-11-15)
등록번호
US-9394350
(2016-07-19)
발명자
/ 주소
Fikes, John D.
Ishioka, Glen
Sette, Alessandro
Chesnut, Robert W.
출원인 / 주소
OSE PHARMA INTERNATIONAL SA
인용정보
피인용 횟수 :
0인용 특허 :
4
초록
A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
대표청구항▼
1. A composition comprising an adjuvant and a peptide comprising a cytotoxic T-cell lymphocyte (CTL) epitope KVFGSLAFV (SEQ ID NO: 7) and a peptide comprising a cytotoxic T-cell lymphocyte (CTL) epitope YLSGADLNL (SEQ ID NO:8), each peptide being less than 15 amino acid residues in length, and the c
1. A composition comprising an adjuvant and a peptide comprising a cytotoxic T-cell lymphocyte (CTL) epitope KVFGSLAFV (SEQ ID NO: 7) and a peptide comprising a cytotoxic T-cell lymphocyte (CTL) epitope YLSGADLNL (SEQ ID NO:8), each peptide being less than 15 amino acid residues in length, and the composition further comprising (a) at least three additional peptides, wherein each of said three peptides is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope selected from the group consisting of KLBPVQLWV (SEQ ID NO:6),SMPPPGTRV (SEQ ID NO:5),IMIGHLVGV (SEQ ID NO:9),LLTFWNPPV (SEQ ID NO:4),KVAEIVHFL (SEQ ID NO:10),RLLQETELV (SEQ ID NO:2), andYLQLVFGIEV (SEQ ID NO:3). 2. The composition of claim 1, further comprising (b) a fourth peptide, wherein said fourth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope selected from the group consisting of KLBPVQLWV (SEQ ID NO:6),SMPPPGTRV (SEQ ID NO:5),IMIGHLVGV (SEQ ID NO:9),LLTFWNPPV (SEQ ID NO:4),KVAEIVHFL (SEQ ID NO:10),RLLQETELV (SEQ ID NO:2), andYLQLVFGIEV (SEQ ID NO:3). 3. The composition of claim 2, further comprising (c) a fifth peptide, wherein said fifth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope selected from the group consisting of KLBPVQLWV (SEQ ID NO:6),SMPPPGTRV (SEQ ID NO:5),IMIGHLVGV (SEQ ID NO:9),LLTFWNPPV (SEQ ID NO:4),KVAEIVHFL (SEQ ID NO:10),RLLQETELV (SEQ ID NO:2), andYLQLVFGIEV (SEQ ID NO:3). 4. The composition of claim 3, further comprising (d) a sixth peptide, wherein said sixth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope selected from the group consisting of KLBPVQLWV (SEQ ID NO:6),SMPPPGTRV (SEQ ID NO:5),IMIGHLVGV (SEQ ID NO:9),LLTFWNPPV (SEQ ID NO:4),KVAEIVHFL (SEQ ID NO:10),RLLQETELV (SEQ ID NO:2), andYLQLVFGIEV (SEQ ID NO:3). 5. The composition of claim 4, further comprising (e) a seventh peptide, wherein said seventh peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope selected from the group consisting of KLBPVQLWV (SEQ ID NO:6),SMPPPGTRV (SEQ ID NO:5),IMIGHLVGV (SEQ ID NO:9),LLTFWNPPV (SEQ ID NO:4),KVAEIVHFL (SEQ ID NO:10),RLLQETELV (SEQ ID NO:2), andYLQLVFGIEV (SEQ ID NO:3). 6. The composition according to claim 1, further comprising an additional peptide, wherein said additional peptide is less than 25 amino acid residues in length and comprises a helper T lymphocyte (HTL) epitope. 7. The composition according to claim 6, wherein said additional peptide is a pan-DR binding peptide. 8. The composition according to claim 7, wherein said pan-DR binding peptide comprises the amino acid sequence aKXVAAWTLKAAa (SEQ ID NO:1). 9. The composition according to claim 1, further comprising a liposome. 10. The composition according to claim 1, further comprising a lipid. 11. A composition according to claim 1, further comprising a pharmaceutical excipient.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (4)
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated.
Melief Cornelius J. M. (Leiden NLX) Visseren M. W. (Leiden NLX) van der Burg Sjoerd (Leiden NLX) van der Bruggen Pierre (Brussels BEX) Boon-Falleur Thierry (Brussels BEX), Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses.
Melief Cornelis J. M.,NLX ; Visseren Marjan J. W.,NLX ; Kast W. Martin,NLX ; van der Bruggen Pierre,BEX ; Boon-Falleur Thierry,BEX, Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof.
Celis Esteban ; Kubo Ralph ; Serra Horacio ; Tsai Van ; Wentworth Peggy, Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of CTL.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.